ArticleJournal of neuro-oncology2026
CD34 and p16 expression in central nervous system solitary fibrous tumors: an exploratory clinicopathologic study.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCentral nervous system solitary fibrous tumors (CNS SFTs) are rare mesenchymal neoplasms. The 2021 World Health Organization (WHO) classification recognizes a single SFT entity characterized by NAB2::STAT6-associated biology. This study evaluated clinicopathologic and immunohistochemical features, with particular emphasis on STAT6, CD34, and p16 expression.
methodsWe retrospectively reviewed 25 CNS SFTs identified between 2004 and 2024. Clinical, radiologic, histologic, immunohistochemical, treatment, and outcome data were collected. Histologic slides were reviewed by two neuropathologists. Immunohistochemistry for STAT6, CD34, and p16 was performed; molecular testing was unavailable.
resultsThe cohort included 13 men and 12 women, with a mean age of 51 years. Among tumors with available site data, most were intracranial. WHO grades were grade 1 in 40%, grade 2 in 24%, and grade 3 in 36%. Nuclear STAT6 expression was present in all cases. CD34 expression was greatest in grade 1 tumors, whereas p16 expression was numerically highest in grade 3 tumors; neither marker showed a statistically significant association with recurrence. Tumor size increased across WHO grades. Outcome analyses were limited by few events and heterogeneous follow-up.
conclusionCNS SFTs are clinicopathologically heterogeneous. STAT6 was a consistent diagnostic marker in this cohort. CD34 and p16 showed grade-related numerical patterns, but their prognostic value was not established. Larger, molecularly confirmed cohorts with standardized long-term follow-up are required.
Indexed as
Identifiers
42560553What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.